Earnings ·
ImageneBio reported a net loss of $10.2 million, or $0.63 per share, for the quarter ended June 30, 2026, compared to…
IMAImageneBio, Inc.
ImageneBio reported a net loss of $10.2 million, or $0.63 per share, for the quarter ended June 30, 2026, compared to a $10.7 million loss in the prior year period. Research and development expenses increased to $6.7 million from $5.7 million, while general and administrative expenses rose to $5.1 million from $1.7 million due to personnel-related costs. The company held $136.2 million in cash and marketable securities as of June 30, 2026, providing funding through the first quarter of 2028. Clinical updates include continued enrollment in the Phase 2b ADAPTIVE trial for atopic dermatitis and plans to initiate a Phase 2 study for alopecia areata in 2026. The company also appointed Yanina Grant-Huerta as CFO and Matt Robbins as General Counsel, while Dr. Ben Porter-Brown transitioned to a consulting role. ImageneBio is a clinical-stage biotechnology company developing therapeutics for immunological and autoimmune diseases.